Compare Trane Technologies plc (TT) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trane Technologies plc vs Travere Therapeutics Inc. Common Stock — how do they compare? Trane Technologies plc trades at $471.85 (market cap $105.17B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Trane Technologies plc is far larger — about 21.6× Travere Therapeutics Inc. Common Stock's market cap, and Trane Technologies plc pays a 0.88% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| TT | TVTX | |
|---|---|---|
Market Cap | $105.17B | $4.88B |
Volume | 1,040,183 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $503.46 | $67.52 |
52-Week Low | $376.43 | $26.79 |
Enterprise Value | $108.47B | $5.01B |
Dividend Yield | 0.88% | — |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Trane Technologies plc
Trane Technologies plc is a global climate solutions company that designs, manufactures, and services heating, ventilation, and air conditioning (HVAC) and transport refrigeration equipment under its Trane and Thermo King brands.
Read more on TT →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
